KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gilead Sciences (GILD) Raw Materials (2009 - 2015)

Gilead Sciences posted quarterly Raw Materials of $1.3 billion for Q4 2015, up 46.53% year-on-year from $909.0 million in Q4 2014, and up 46.53% on a QoQ basis from $909.0 million in Q4 2014.

Gilead Sciences (GILD) has 7 years of Raw Materials data on file, last reported at $1.3 billion in Q4 2015.

  • For the quarter ending Q4 2015, Raw Materials rose 46.53% year-over-year to $1.3 billion; the trailing twelve-month figure through Dec 2015 stood at $1.3 billion (up 46.53% YoY), and the FY2015 full-year result was $1.3 billion, up 46.53% from the prior year.
  • Raw Materials for Q4 2015 stood at $1.3 billion, up from $909.0 million in the prior quarter.
  • Across five years, Raw Materials topped out at $1.3 billion in Q4 2015 and bottomed at $559.2 million in Q1 2011.
  • The 5-year median for Raw Materials is $866.4 million (2011), against an average of $872.3 million.
  • The widest annual swing landed in 2011, when Raw Materials surged 96.23%; it then slipped 13.38% in 2014.
  • A 5-year view of Raw Materials shows it stood at $697.6 million in 2011, then grew by 18.48% to $826.5 million in 2012, then rose by 26.96% to $1.0 billion in 2013, then retreated by 13.38% to $909.0 million in 2014, then jumped by 46.53% to $1.3 billion in 2015.
  • The last three Raw Materials figures came in at $1.3 billion (Q4 2015), $909.0 million (Q4 2014), and $944.9 million (Q2 2014), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Novartis Ag 107,124,802.25 Bn 107,124,802.25 Bn -
2 Eli Lilly 969.00 Bn 963.72 Bn 16.22 Bn
3 Johnson & Johnson 539.46 Bn 517.41 Bn 15.96 Bn
4 AbbVie 376.92 Bn 367.57 Bn 10.78 Bn
5 Merck 285.00 Bn 279.35 Bn 12.09 Bn
6 Amgen 177.58 Bn 165.55 Bn 5.87 Bn
7 Gilead Sciences 163.22 Bn 155.50 Bn 5.52 Bn
8 Pfizer 145.86 Bn 133.09 Bn -1.21 Bn
9 Bristol Myers Squibb 111.90 Bn 101.44 Bn 8.07 Bn
10 Gsk 88.34 Bn 83.66 Bn -

Historic Data

Download Data 🔒
DateValue
Dec 31, 2015 1.33 Bn
Dec 31, 2014 909.00 Mn
Jun 30, 2014 944.89 Mn
Dec 31, 2013 1.05 Bn
Dec 31, 2012 826.55 Mn
Dec 31, 2011 697.62 Mn
Sep 30, 2011 866.41 Mn
Jun 30, 2011 665.25 Mn
Mar 31, 2011 559.16 Mn
Dec 31, 2010 408.02 Mn
Sep 30, 2010 441.53 Mn
Dec 31, 2009 333.58 Mn